Axsome Therapeutics, Inc. 19X.F Stock
Axsome Therapeutics, Inc. Price Chart
Axsome Therapeutics, Inc. 19X.F Financial and Trading Overview
Axsome Therapeutics, Inc. stock price | 62.78 EUR |
Previous Close | 74.92 EUR |
Open | 76.24 EUR |
Bid | 76.34 EUR x 0 |
Ask | 78.42 EUR x 0 |
Day's Range | 76.24 - 76.24 EUR |
52 Week Range | 20.44 - 76.52 EUR |
Volume | 90 EUR |
Avg. Volume | 63 EUR |
Market Cap | 3.55B EUR |
Beta (5Y Monthly) | 1.913732 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.92 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 86.21 EUR |
19X.F Valuation Measures
Enterprise Value | 3.17B EUR |
Trailing P/E | N/A |
Forward P/E | -19.906006 |
PEG Ratio (5 yr expected) | 0.15 |
Price/Sales (ttm) | 24.545261 |
Price/Book (mrq) | 29.68847 |
Enterprise Value/Revenue | 21.891 |
Enterprise Value/EBITDA | -22.411 |
Trading Information
Axsome Therapeutics, Inc. Stock Price History
Beta (5Y Monthly) | 1.913732 |
52-Week Change | 257.43% |
S&P500 52-Week Change | 20.43% |
52 Week High | 76.52 EUR |
52 Week Low | 20.44 EUR |
50-Day Moving Average | 64.6 EUR |
200-Day Moving Average | 60.4 EUR |
19X.F Share Statistics
Avg. Volume (3 month) | 63 EUR |
Avg. Daily Volume (10-Days) | 24 EUR |
Shares Outstanding | 43.57M |
Float | 31.77M |
Short Ratio | N/A |
% Held by Insiders | 18.49% |
% Held by Institutions | 70.77% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -109.75% |
Operating Margin (ttm) | -98.98% |
Gross Margin | 91.94% |
EBITDA Margin | -97.68% |
Management Effectiveness
Return on Assets (ttm) | -37.45% |
Return on Equity (ttm) | -250.91% |
Income Statement
Revenue (ttm) | 144.61M EUR |
Revenue Per Share (ttm) | 3.45 EUR |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | 45.94M EUR |
EBITDA | -141259392 EUR |
Net Income Avi to Common (ttm) | -158719648 EUR |
Diluted EPS (ttm) | -3.7 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 246.52M EUR |
Total Cash Per Share (mrq) | 5.66 EUR |
Total Debt (mrq) | 147.72M EUR |
Total Debt/Equity (mrq) | 132.12 EUR |
Current Ratio (mrq) | 3.025 |
Book Value Per Share (mrq) | 2.568 |
Cash Flow Statement
Operating Cash Flow (ttm) | -89678800 EUR |
Levered Free Cash Flow (ttm) | -21893428 EUR |
Profile of Axsome Therapeutics, Inc.
Country | Germany |
State | NY |
City | New York |
Address | 22 Cortlandt Street |
ZIP | 10007 |
Phone | 212 332 3241 |
Website | https://www.axsome.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 393 |
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Q&A For Axsome Therapeutics, Inc. Stock
What is a current 19X.F stock price?
Axsome Therapeutics, Inc. 19X.F stock price today per share is 62.78 EUR.
How to purchase Axsome Therapeutics, Inc. stock?
You can buy 19X.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Axsome Therapeutics, Inc.?
The stock symbol or ticker of Axsome Therapeutics, Inc. is 19X.F.
Which industry does the Axsome Therapeutics, Inc. company belong to?
The Axsome Therapeutics, Inc. industry is Biotechnology.
How many shares does Axsome Therapeutics, Inc. have in circulation?
The max supply of Axsome Therapeutics, Inc. shares is 48.65M.
What is Axsome Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Axsome Therapeutics, Inc. PE Ratio is now.
What was Axsome Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Axsome Therapeutics, Inc. EPS is -4.92 EUR over the trailing 12 months.
Which sector does the Axsome Therapeutics, Inc. company belong to?
The Axsome Therapeutics, Inc. sector is Healthcare.